
AAOS 2016: Liposomal vs standard bupivacaine in TKA; no difference in analgesic efficacy

AAOS 2016: Liposomal vs standard bupivacaine in TKA; no difference in analgesic efficacy
Periarticular Liposomal Bupivacaine Offers No Benefit Over Bupivacaine in Total Knee Arthroplasty
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
162 patients scheduled for primary total knee arthroplasty were randomized to periarticular injections with either liposomal bupivacaine or standard bupivacaine. Pain scores and narcotic consumption were recorded over the first 4 postoperative days while function and health-related quality of life were assessed at 4-6 weeks postoperatively. Results demonstrated no significant difference between gr...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Learn about our AI Driven
High Impact Search Feature

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.